Mitsubishi Tanabe Pharma America
Colin Watson Ph.D. is an accomplished professional in the pharmaceutical industry with extensive experience in medical affairs and leadership roles. Currently serving as Director of MSLs at Mitsubishi Tanabe Pharma America since December 2023, Colin previously held positions as Senior Director and Head of MSLs at BioXcel Therapeutics, Inc. from January 2021 to October 2023, and as Senior Director of Medical Operations and Medical Director of Neurology at GE Healthcare from July 2016 to January 2021. Other notable roles include Field Medical Director at FORUM Pharmaceuticals and Neuroscience Regional Medical & Research Specialist at Pfizer. Colin holds a PhD in Molecular Biology and a BSc with Honours in Agricultural Sciences from the University of Nottingham.
This person is not in any offices
Mitsubishi Tanabe Pharma America
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: http://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf